Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Parabilis Medicines Q3 2026 Results: Net Loss of $44.5M, Loss Widens

Parabilis Medicines, Inc. is a clinical-stage biotechnology company that remains pre-revenue and has incurred significant losses since inception. As of November 9, 2026, the company had approximately 125.3 million total shares outstanding and is focused on advancing its Helicon discovery platform and lead product candidate, zolucatetide.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2.10.0
Net income-44.5-33.5
EPS (diluted, $ a share)$-0.36$-21.66

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: PBLS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Parabilis Medicines, Inc.: key numbers

Share price
$28.45Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Parabilis Medicines, Inc.

All →
7:08 AM ET 8-K
Financial Results

Parabilis Medicines Financial Results

Parabilis Medicines reported third-quarter 2026 financial results, ending the period with $1.1 billion in cash and marketable securities. The company reached alignment with the FDA on the Phase 3 registrational trial design for zolucatetide in desmoid tumors, with initiation planned for the first half of 2027. Additionally, the company entered a clinical collaboration with Revolution Medicines to evaluate zolucatetide in combination therapies for metastatic colorectal cancer.

Term
Q3 2026

“With each successive clinical update, we are building a stronger foundation for zolucatetide as a unique medicine with the potential to make a meaningful difference for patients across multiple diseases.”

Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President

“The progress across our portfolio continues to strengthen our conviction in the ability of our Helicon platform to repeatedly translate breakthrough science into medicines that can meaningfully improve patients’ lives.”

Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President
4:18 PM ET 8-K
Capacity Expansion

Parabilis Medicines Capacity Expansion

Parabilis Medicines entered into a lease amendment to expand its corporate headquarters in Cambridge, Massachusetts, by 33,525 square feet. The agreement also extends the existing lease term from March 2031 through December 2037 and includes options for two additional five-year extensions.

Counterparty
LS 400/500 CDP, LLC
Term
through Dec 2037

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.